Regeneron: Covid-19 clinical trial begins
(CercleFinance.com) - Regeneron Pharmaceuticals has announced that it has begun the first clinical trial for REGN-COV2, an investigational "cocktail" of two antibodies for the prevention and treatment of Covid-19.
This program will consist of four separately studied populations: two for treatment and two for prevention. The first two studies will evaluate safety and efficacy in both inpatients and outpatients.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This program will consist of four separately studied populations: two for treatment and two for prevention. The first two studies will evaluate safety and efficacy in both inpatients and outpatients.
Copyright (c) 2020 CercleFinance.com. All rights reserved.